Serum concentrations of Krebs von den Lungen-6 as prognostic biomarker in patients with silicosis

Krebs von den Lungen-6 的血清浓度作为矽肺患者的预后生物标志物

阅读:1

Abstract

INTRODUCTION: KL-6, a pneumocyte derived biomarker, is increased in patients with interstitial lung diseases (ILDs). We aimed to investigate the role of serum KL-6 as a diagnostic and prognostic biomarker in silica-exposed workers. MATERIAL AND METHOD: We studied 108 silica-exposed subjects and 25 healthy controls. Chest radiography (CXR), pulmonary function tests, inflammatory markers were collected. Progressive massive fibrosis (PMF) was defined according to the ILO classification. KL-6 was measured in serum by fully automated CLEIA at first presentation at our institution, intended as baseline visit, with a time point from the initial exposure variable for each patient. RESULTS: PMF was present in 23 subjects. Serum KL-6 levels were significantly higher in subjects with PMF than in controls, exposed workers or simple silicosis (p<0.001). In PMF, serum KL-6 positively correlated with C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR), and negatively with forced vital capacity (FVC) % predicted. At a cut-off of 436 U/mL, serum KL-6 differentiated exposed workers from PMF with a specificity and sensitivity exceeding 90% (p<0.0001), while a cut-off of 445 U/mL differentiated simple silicosis from PMF (p<0.0001). In the multivariate analysis, serum KL-6 levels were independently associated with risk of fibrosis. CONCLUSION: Serum KL-6 appears to be a promising biomarker for the occurrence and progression of PMF in silica-exposed workers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。